BerGenBio ASA publishes Annual Report for 2018

Bergen, Norway, 20 February 2019 – The Board of Directors of BerGenBio ASA (OSE:BGBIO) has today approved the Company's Annual Report for 2018 including the complete 2018 Annual Accounts with notes. The report is attached and available for download at www.bergenbio.com in the section: Investors/Financial Reports.

-End-


About BerGenBio ASA 

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for advanced and aggressive cancers. 

The company’s proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent. 

In parallel, BerGenBio is developing companion diagnostics test to identify patient populations most likely to benefit from bemcentinib; this is expected to facilitate more efficient registration trials and support a precision medicine-based commercialisation strategy. 

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). 

www.bergenbio.com 


Contacts 

Richard Godfrey 
CEO, BerGenBio ASA 
+47 917 86 304 

Rune Skeie, CFO, BerGenBio ASA 
rune.skeie@bergenbio.com 
+47 917 86 513 

Media Relations in Norway 

Jan Petter Stiff, Crux Advisers 
stiff@crux.no 
+47 995 13 891 

International Media Relations 

Mary-Jane Elliott, Chris Welsh, Nicholas Brown, Carina Jurs, Consilium Strategic Communications 
bergenbio@consilium-comms.com 
+44 20 3709 5700


Forward looking statements 

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements  

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. 

Tags:

About Us

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create important new therapeutic options for cancer patients.